New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes and established cardiovascular disease
INGELHEIM, Germany & INDIANAPOLIS, Ind. -- (BUSINESS WIRE) -- Today, the journal Circulation published novel results based on data from the landmark EMPA-REG OUTCOME® trial, which sugges......
